Stocks › REGN

REGENERON PHARMACEUTICALS, INC.

REGN·Nasdaq·United States United States·USD
$920.69
-2.65 (-0.29%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
REGN
REGENERON PHARMACEUTICALS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
REGNS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of REGN by members of U.S. Congress · 244 on record · 15 in the last 12 months
All congressional trades →
PoliticianStockTypeFiledTraded
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Stock Purchase
$1,001 - $15,000
Nov 5, 2026 Oct 7, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Common Stock Sale
$1,001 - $15,000
Oct 8, 2026 Sep 4, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Stock Purchase
$1,001 - $15,000
Aug 8, 2026 Jul 7, 2026 Filing ↗
Alan ArmstrongAlan ArmstrongSenate · R · OK REGNREGENERON PHARMACEUTICALS, INC. · Stock Purchase
$1,001 - $15,000
Jul 21, 2026 Mar 27, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Stock Sale
$1,001 - $15,000
Jul 7, 2026 Jun 2, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · CMN Purchase
$1,001 - $15,000
Jul 7, 2026 Jun 16, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Common Stock Sale
$1,001 - $15,000
Jun 10, 2026 May 15, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Stock Sale
$1,001 - $15,000
Jun 10, 2026 May 1, 2026 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Stock Sale
$1,001 - $15,000
Jun 8, 2026 May 15, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Stock Purchase
$1,001 - $15,000
May 11, 2026 Apr 13, 2026 Filing ↗
Julia LetlowJulia LetlowHouse · R · LA REGNREGENERON PHARMACEUTICALS, INC. · Stock Purchase
$1,001 - $15,000
Mar 12, 2026 Feb 12, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Common Stock Purchase
$1,001 - $15,000
Feb 6, 2026 Jan 23, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Common Stock Sale
$1,001 - $15,000
Feb 6, 2026 Jan 29, 2026 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Stock Purchase
$1,001 - $15,000
Dec 15, 2025 Nov 18, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Common Stock Purchase
$1,001 - $15,000
Dec 8, 2025 Nov 3, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Common Stock Purchase
$1,001 - $15,000
Oct 3, 2025 Sep 29, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Stock Purchase
$1,001 - $15,000
Sep 9, 2025 Aug 26, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Common Stock Purchase
$1,001 - $15,000
Sep 9, 2025 Aug 4, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Common Stock Sale
$1,001 - $15,000
Aug 7, 2025 Jul 1, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Common Stock Sale
$1,001 - $15,000
Aug 7, 2025 Jul 25, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Stock Purchase
$1,001 - $15,000
Jun 10, 2025 May 19, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA REGNREGENERON PHARMACEUTICALS, INC. · Common Stock Sale
$1,001 - $15,000
Jun 10, 2025 May 28, 2025 Filing ↗
Robert P. Bresnahan, Jr.Robert P. Bresnahan, Jr.House · R · PA REGNREGENERON PHARMACEUTICALS, INC. · Stock Purchase
$1,001 - $15,000
Jun 9, 2025 May 15, 2025 Filing ↗
Byron DonaldsByron DonaldsHouse · R · FL REGNREGENERON PHARMACEUTICALS, INC. · Stock Sale
$1,001 - $15,000
May 24, 2025 Apr 10, 2025 Filing ↗
Byron DonaldsByron DonaldsHouse · R · FL REGNREGENERON PHARMACEUTICALS, INC. · Stock Sale
$1,001 - $15,000
May 24, 2025 Apr 10, 2025 Filing ↗

Whale Activity

Position changes in REGN reported for 2026-09-30 by 1523 institutional filers
Increased: 561New: 192Held: 178Decreased: 443Closed: 87No prior filing: 62
  • Increased561
  • New192
  • Held178
  • Decreased443
  • Closed87
  • No prior filing62
FilerSharesValueChange
BlackRock, Inc.8.8M$6.71Bdecreased
VANGUARD CAPITAL MANAGEMENT LLC6.5M$4.95Bdecreased
STATE STREET CORP4.9M$3.70Bincreased
DODGE & COX4.8M$3.62Bdecreased
Invesco Ltd.3.7M$2.82Bdecreased
FRANKLIN TEMPLETON INC3.0M$2.75Bincreased
JPMORGAN CHASE & CO3.3M$2.48Bdecreased
VANGUARD PORTFOLIO MANAGEMENT LLC3.1M$2.36Bdecreased
GEODE CAPITAL MANAGEMENT, LLC2.6M$1.99Bincreased
Nuveen, LLC2.0M$1.48Bdecreased
LOOMIS SAYLES & CO L P1.7M$1.30Bdecreased
MORGAN STANLEY1.4M$1.04Bdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by REGN insiders, by quarter · Form 4
-100.0K-50.0K050.0K100.0K2025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: -7,6912025 Q42026 Q1: -5,3742026 Q12026 Q2: -2002026 Q22026 Q3: -4,1462026 Q32026 Q4: -60.1K2026 Q4

Recent Insider Transactions

7,024 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
MURPHY ANDREW JCo-Chief Scientific Officer Sale −93 $949.69 $88K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −74 $950.61 $70K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −671 $953.69 $640K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −584 $961.45 $561K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −506 $959.45 $485K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −346 $956.70 $331K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −340 $964.36 $328K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −313 $955.48 $299K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −313 $954.45 $299K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −298 $951.75 $284K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −295 $962.70 $284K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −257 $960.65 $247K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −255 $963.60 $246K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −244 $958.27 $234K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −220 $952.75 $210K Nov 17, 2026 Form 4 ↗
MURPHY ANDREW JCo-Chief Scientific Officer Sale −202 $957.53 $193K Nov 17, 2026 Form 4 ↗
SING GEORGE LDirector · Director Sale −465 $958.11 $446K Nov 17, 2026 Form 4 ↗
SING GEORGE LDirector · Director Sale −359 $957.49 $344K Nov 17, 2026 Form 4 ↗
SING GEORGE LDirector · Director Sale −176 $956.96 $168K Nov 17, 2026 Form 4 ↗
McCourt MarionEVP Commercial Sale −66 $959.46 $63K Nov 16, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding REGN · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
3.3M$2.04B0.09%Jun 30, 2026
Dodge & Cox Stock Fund
Dodge & Cox Funds
3.1M$1.95B1.64%Jun 30, 2026
VANGUARD 500 INDEX FUND
VANGUARD INDEX FUNDS
2.6M$1.61B0.10%Jun 30, 2026
Invesco QQQ Trust, Series 12.2M$1.36B0.28%Jun 30, 2026
Fidelity 500 Index Fund
Fidelity Concord Street Trust
1.3M$1.04B0.12%Aug 31, 2026
Putnam Large Cap Value Fund1.2M$878.6M1.59%Jul 31, 2026
iShares Core S&P 500 ETF
iShares Trust
1.4M$857.0M0.10%Jun 30, 2026
VANGUARD HEALTH CARE FUND
VANGUARD SPECIALIZED FUNDS
1.1M$817.7M2.14%Jul 31, 2026
State Street(R) SPDR(R) S&P 500(R) ETF Trust1.2M$755.1M0.10%Jun 30, 2026
VANGUARD MID-CAP INDEX FUND
VANGUARD INDEX FUNDS
1.1M$696.0M0.31%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list REGN's shares (CUSIP 75886F107), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • JPMORGAN CHASE & CO.SCHEDULE 13G/A · passive (13G) · 4.7M shares4.4%
    Jun 5, 2025 · ↗
  • JPMORGAN CHASE & CO.SCHEDULE 13G/A · passive (13G) · 5.5M shares5.1%
    Apr 22, 2025 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming regeneron pharmaceuticals as client
$0$1.3M$2.5M$3.8M$5.0M2023 Q1: $570K2023 Q2: $480K2023 Q3: $510K2023 Q4: $540K20232024 Q1: $540K2024 Q2: $510K2024 Q3: $510K2024 Q4: $570K20242025 Q1: $510K2025 Q2: $870K2025 Q3: $830K2025 Q4: $870K20252026 Q1: $900K2026 Q2: $940K2026 Q3: $860K2026
  • CRANE STRATEGIESREGENERON PHARMACEUTICALS, INC. · 2026 Q3 · BUD$50K
    Filing ↗
  • REGENERON PHARMACEUTICALS, INCREGENERON PHARMACEUTICALS, INC · 2026 Q3 · CPT, TRD, TAX, HCR$590K
    Filing ↗
  • BGR GOVERNMENT AFFAIRSREGENERON PHARMACEUTICALS, INC. · 2026 Q3 · HCR$90K
    Filing ↗
  • ARNOLD & PORTER KAYE SCHOLER LLPREGENERON PHARMACEUTICALS, INC. · 2026 Q3 · HCR$10K
    Filing ↗
  • CHECKMATE GOVERNMENT RELATIONSREGENERON PHARMACEUTICALS INC. · 2026 Q3 · HCR$90K
    Filing ↗

Government Contracts

Federal awards to regeneron pharmaceuticals · USAspending
$1.25BAwarded · 2 contracts on record
  • Department of Health and Human ServicesIGF::OT::IGF$973.6M
    Sep 30, 2017 · ↗
  • Department of Health and Human ServicesIGF::OT::IGF - REGENERON OTHER TRANSACTION AUTHORITY (OTA) AWARD$278.8M
    Sep 21, 2017 · ↗

U.S. Patents

Recent USPTO applications naming REGENERON PHARMACEUTICALS, INC.

No USPTO patent applications found for REGENERON PHARMACEUTICALS, INC..

Annual Financials

From REGN's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$14.34B$14.20B$13.12B$12.17B$16.07B
Operating income$3.58B$3.99B$4.05B$4.74B$8.95B
Net income$4.50B$4.41B$3.95B$4.34B$8.08B
Diluted EPS$41.48$38.34$34.77$38.22$71.97
Operating cash flow$4.98B$4.42B$4.59B$5.01B$7.08B
Cash and equivalents$3.12B$2.49B$2.73B$3.11B$2.89B
Total assets$40.56B$37.76B$33.08B$29.21B$25.43B
Total liabilities$9.30B$8.41B$7.11B$6.55B$6.67B
Shareholders' equity$31.26B$29.35B$25.97B$22.66B$18.77B

As REGENERON PHARMACEUTICALS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 4, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in REGN's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsOct 30, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 2.02, 8.01Material agreement · Results of operations · Other eventsOct 6, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 9.01Officer / director changeSep 30, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsJul 30, 2026
    EDGAR ↗
  • 8-K · Items 2.02Results of operationsJul 6, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteJun 17, 2026
    EDGAR ↗

About REGENERON PHARMACEUTICALS, INC.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersTARRYTOWN, NY
IncorporatedNY
Former namesREGENERON PHARMACEUTICALS INC